In addition, also C5a concentrations were significantly higher in treatment-naïve (30.4 ± 4.3 ng/ml) and ERT-treated FD patients (40.5 ± 6.4 ng/ml) as compared to healthy controls (Figure 1D). This evidence concerns the gene C5AR1 and Fabry disease.